Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-05-16
2006-05-16
Campell, Bruce R. (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C424S093700
Reexamination Certificate
active
07045502
ABSTRACT:
According to the invention there is provided the use of melagatran, or a pharmaceutically-acceptable derivative thereof, for the manufacture of a medicament for the treatment of Type I diabetes.
REFERENCES:
patent: 6683054 (2004-01-01), Kirk
patent: WO-94/29336 (1994-12-01), None
patent: WO-97/23499 (1997-07-01), None
patent: WO-00/41716 (2000-07-01), None
patent: WO-00/45837 (2000-08-01), None
patent: WO-02/36157 (2002-05-01), None
Gustafsson D, et al., Throm Haemost., 1998, 79(1), pp. 110-118.
Gustaffson, et al., 1998, Tromb Haemost, 79, 110-8.
Shapiro AM., et al., N. Engl. J. Med., 2000, 343, 230-8.
Bennet, W., et al., 1999, Diabetes, 48, 1907-14.
Soria, et al., Diabetes, 2000, 49, 1-6.
Shapiro, A.M. James, et al., “Islet Transplantation in Seven Patients with Type 1 Diabetes Mellitus Using a Glucocorticoid-Free Immunosuppressive Regimen,” The New England Journal of Medicine, 343(4):220-238 (2000).
Ozmen, L., et al., “Inhibition of Thrombin Abrogates the Instant Blood-Mediated Inflammatory Reaction Triggered by Isolated Human Islets, Possible Application of the Thrombin Inhibitor Melagatran in Clinical Islet Transplantation,” Diabetes, 51:1779-1784 (2002).
Boker, A., et al., “Human Islet Transplantation: Update,” World J. Surg., 25:481-486 (2001).
Bennet, W., et al., “Incompatibility Between Human Blood and Isolated Islets of Langerhans, A Finding With Implications for Clinical Intraportal Islet Transplantation?” Diabetes, 48:1907-1914 (1999).
Sefton, M.V., et al., “Making microencapsulation work: conformal coating, immobilization gels and in vivo performance,” Journal of Controlled Release, 65:173-186 (2000).
Hill, R.S., et al., “Immunoisolation of Adult Porcine Islets for the Treatment of Diabetes Mellitus, The Use of Photopolymerizable Polyethylene Glycol in the Conformal Coating of Mass-isolated Porcine Islets,” Annals of the New York Academy of Sciences, 831:332-343.
Korsgren Olle
Nilsson Bo
AstraZeneca AB
Campell Bruce R.
Fish & Neave IP Group Ropes & Gray LLP
Gudibande Satyanarayana R.
LandOfFree
Use of melagatran for the manufacture of a medicament for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of melagatran for the manufacture of a medicament for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of melagatran for the manufacture of a medicament for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3543466